Trevi Therapeutics, Inc. (TRVI)
Nasdaq: TRVI · Pharmaceutical Preparations · New Haven, CT · filing with the SEC since 2012
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
| Report filed | Mar 17, 2026 | Mar 18, 2025 | Mar 20, 2024 | Mar 16, 2023 | Mar 17, 2022 | Mar 25, 2021 | Mar 16, 2020 | · |
| Research and development | 33,478 | 39,377 | 23,683 | 19,834 | 22,984 | 22,328 | 19,339 | 14,072 |
| General and administrative | 15,850 | 12,147 | 10,240 | 10,073 | 9,492 | 10,161 | 7,306 | 4,336 |
| Total operating expenses | 49,328 | 51,524 | 33,923 | 29,907 | 32,476 | 32,489 | 26,645 | 18,408 |
| Operating income | -49,328 | -51,524 | -33,923 | -29,907 | -32,476 | -32,489 | -26,645 | -18,408 |
| Interest expense | 0 | 4 | 391 | 1,163 | 1,202 | 456 | · | 174 |
| Interest and investment income | 6,536 | 3,602 | 4,748 | · | · | · | · | · |
| Interest income (expense), net | · | · | 4,748 | 1,740 | 10 | 178 | 792 | 156 |
| Other income (expense), net | -31 | -15 | 469 | 289 | -375 | · | · | · |
| Total non-operating income (expense) | 6,505 | 3,583 | 4,826 | 719 | -1,485 | -287 | 577 | -2,261 |
| Income before income taxes | -42,823 | -47,941 | -29,097 | -29,188 | -33,961 | -32,776 | -26,068 | -20,669 |
| Income tax expense | -64 | -30 | -32 | -36 | -21 | -18 | -18 | -124 |
| Net income | -42,759 | -47,911 | -29,065 | -29,152 | -33,940 | -32,758 | -26,050 | -20,545 |
| Net income to common shareholders | · | · | · | · | · | -32,758 | -26,754 | -25,577 |
| Earnings per share, basic | -0.32 | -0.47 | -0.29 | -0.45 | -1.49 | · | · | · |
| Earnings per share, diluted | -0.32 | -0.47 | -0.29 | -0.45 | -1.49 | · | · | · |
| Earnings per share, basic and diluted | · | · | · | · | -1.49 | -1.81 | -2.28 | -58.44 |
| Weighted average shares, basic | 134,747,198 | 101,971,873 | 99,033,373 | 64,541,911 | 22,841,481 | · | · | · |
| Weighted average shares, diluted | 134,747,198 | 101,971,873 | 99,033,373 | 64,541,911 | 22,841,481 | · | · | · |
| Weighted average shares, basic and diluted | · | · | · | · | 22,841,481 | 18,059,011 | 11,735,781 | 437,610 |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Research and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest expense what its borrowing cost
us-gaap:InterestExpenseNonoperating
us-gaap:InterestExpenseInterest and investment income what its cash and investments earned
us-gaap:InvestmentIncomeInterestInterest income (expense), net interest earned less interest paid, outside the business
us-gaap:InterestIncomeExpenseNonoperatingNetOther income (expense), net gains and costs outside the business
us-gaap:OtherNonoperatingIncomeExpenseTotal non-operating income (expense) everything outside the business, together
us-gaap:NonoperatingIncomeExpenseIncome before income taxes profit before tax
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossNet income to common shareholders what is left for common shareholders
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasicEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedEarnings per share, basic and diluted net income per share, where both counts are the same
us-gaap:EarningsPerShareBasicAndDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstandingWeighted average shares, basic and diluted the average count, where both counts are the same
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted